Phase IIIb trial finds pectelaganan spray beats placebo in infected burns

The wire

1. 01A Phase IIIb trial across 23 centers published in Burns & Trauma randomized 348 patients aged 18 to 65 with moderate infected burns under 10 percent body surface area to 0.2 percent pectelaganan (PL-5) spray or placebo for 14 days.
2. 02The synthetic hybrid antimicrobial peptide disrupts bacterial cells through non-specific mechanisms, which the authors frame as a route around resistance to standard topical antibiotics.
3. 03Adverse event rates did not differ significantly between groups and systemic absorption was undetectable; the findings apply only to moderate infected burns in adults, not severe, pediatric or uninfected wounds. The developer is Jiangsu Protelight.

From the source

A Bee-Derived Peptide Outperforms Placebo in Treating Infected Burns

Burns are rarely a single wound; they are often a battlefield. In the specific case of moderate, infected burns covering less than 10 percent of the body, the clinical priority is not just closing the skin, but stopping the bacterial invasion that prevents closure. Standard topical antibiotics are a first-line defense, but they face a growing threat: resistance. When bacteria adapt to standard dru